as 07-26-2024 4:00pm EST
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Founded: | 1990 | Country: | United States |
Employees: | N/A | City: | FREMONT |
Market Cap: | 735.1M | IPO Year: | 2021 |
Target Price: | $8.63 | AVG Volume (30 days): | 799.4K |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.09 | EPS Growth: | N/A |
52 Week Low/High: | $3.80 - $9.87 | Next Earning Date: | 08-06-2024 |
Revenue: | $200,786,000 | Revenue Growth: | 20.91% |
Revenue Growth (this year): | 10.34% | Revenue Growth (next year): | 18.52% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Yan Ming | CTKB | CHIEF TECHNOLOGY OFFICER | Apr 19 '24 | Sell | $5.87 | 20,000 | $117,400.00 | 5,988,502 | SEC Form 4 |
Yan Ming | CTKB | CHIEF TECHNOLOGY OFFICER | Apr 9 '24 | Sell | $7.00 | 1,500 | $10,500.00 | 6,008,902 | SEC Form 4 |
Yan Ming | CTKB | CHIEF TECHNOLOGY OFFICER | Apr 9 '24 | Sell | $7.01 | 400 | $2,804.00 | 6,008,502 | SEC Form 4 |
Yan Ming | CTKB | CHIEF TECHNOLOGY OFFICER | Mar 18 '24 | Sell | $6.77 | 20,000 | $135,400.00 | 6,030,402 | SEC Form 4 |
Yan Ming | CTKB | CHIEF TECHNOLOGY OFFICER | Mar 18 '24 | Sell | $6.71 | 20,000 | $134,200.00 | 6,010,402 | SEC Form 4 |
Jeanmonod Patrik | CTKB | Chief Financial Officer | Dec 26 '23 | Sell | $9.50 | 3,000 | $28,500.00 | 93,400 | SEC Form 4 |
Yan Ming | CTKB | Chief Technology Officer | Dec 19 '23 | Sell | $9.43 | 20,000 | $188,600.00 | 6,042,103 | SEC Form 4 |
Jeanmonod Patrik | CTKB | Chief Financial Officer | Nov 24 '23 | Sell | $6.94 | 3,000 | $20,820.00 | 96,400 | SEC Form 4 |
Yan Ming | CTKB | Chief Technology Officer | Nov 18 '23 | Sell | $6.03 | 20,000 | $120,600.00 | 7,762,103 | SEC Form 4 |
Jiang Wenbin | CTKB | President and CEO | Nov 7 '23 | Sell | $4.34 | 20,000 | $86,800.00 | 5,275,796 | SEC Form 4 |
Jeanmonod Patrik | CTKB | Chief Financial Officer | Oct 24 '23 | Sell | $4.68 | 3,000 | $14,040.00 | 96,084 | SEC Form 4 |
CTKB Breaking Stock News: Dive into CTKB Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
Simply Wall St.
5 days ago
Argus Research
10 days ago
Argus Research
17 days ago
Zacks
a month ago
GOBankingRates
2 months ago
Business Insider
2 months ago
Insider Monkey
2 months ago
The information presented on this page, "CTKB Cytek Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.